![Xingxing Zang]()
Developing Type 1 Diabetes Therapies—The National Institute of Diabetes and Digestive and Kidney Diseases has awarded nearly $1.9 million over five years to Xingxing Zang, Ph.D., to study new therapies for treating type 1 diabetes (T1D). T1D occurs when the body's T lymphocytes attack and destroy pancreatic beta cells that produce the hormone insulin, which regulates blood sugar levels. Dr. Zang’s lab recently found that the presence of proteins B7x and B7-H3 in the islets of Langerhans (areas of the pancreas containing beta cells) protects beta cells from T-lymphocyte attack. This funding will help explore how these findings can be translated into new T1D therapies. Dr. Zang is associate professor of microbiology & immunology and associate professor of medicine. He also is the Miriam Mandel Faculty Scholar in Cancer Research.
Posted on: Tuesday, November 10, 2015